California Cancer Consortium

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, California Cancer Consortium sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

California Cancer Consortium: 8 sponsored US clinical trials, none currently recruiting.

California Cancer Consortium sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma and Plasma Cell Neoplasm, with 2 trials.

Upper-quartile sponsor footprint

California Cancer Consortium sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 1

Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

NCT00387504
TERMINATED Phase 2

Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

NCT00103103
COMPLETED Phase 1

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

NCT00104923
TERMINATED Phase 2

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00467077
COMPLETED Phase 1

Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00033410
COMPLETED Phase 2

Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00022607
TERMINATED

Irinotecan in Treating Patients With Colorectal Cancer

NCT00003843
COMPLETED Phase 1

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

NCT00002980

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 3

Therapeutic Areas

Multiple Myeloma and Plasma Cell Neoplasm 2
Chronic Myeloproliferative Disorders 1
Unspecified Adult Solid Tumor, Protocol Specific 1
Leukemia 1
Lung Cancer 1
Lymphoma 1

How the California Cancer Consortium early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Multiple Myeloma and Plasma Cell Neoplasm (2 trials), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

California Cancer Consortium: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

California Cancer Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share California Cancer ConsortiumAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
California Cancer Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

California Cancer Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this California Cancer Consortium page

8 registered trials is a research-attention snapshot, not an endorsement of California Cancer Consortium or any single study.

  • None of California Cancer Consortium's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Multiple Myeloma and Plasma Cell Neoplasm is the condition California Cancer Consortium studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma and Plasma Cell Neoplasm trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

California Cancer Consortium pipeline card: 8 registered trials from official public datasets.Report a data error.